Navigation Links
Enzyme to Boost Effect of Tumor Vaccine

The effects of tumor vaccines seem to get boosted by a 'super' form of an enzyme called Akt1. This enzyme is expected //to help extend the life of dendritic cells. These cells are also referred to as the main switch of the immune system that improves the way the T-cells respond to attack a tumor. This was divulged in a report that appears in an electronic media, online in the latest issue of the journal Nature Biotechnology. Researchers from Baylor College of Medicine conducted the study.

The desirable immune response is achieved by maintaining the window of activation longer. This is possible by keeping dendritic cells alive for longer time explained Dr. David Spencer, associate professor of immunology at BCM. 'The longer your dendritic cells are alive and active, the more likely you are to expand the appropriate T-helper repertoire and ultimately the desirable cytotoxic (cell killing) T-lymphocytes.'

'The dendritic cells are the master switch in the immune system. They decide whether there will be a robust immune response or a tempered immune response to pathogens or cancer,' he said. Using a variety of sophisticated laboratory techniques, Spencer and his colleagues found that Akt1 'was in fact essential for dendritic cell survival,' he said. Then they sought to develop a more potent form of Akt1 that would enable the dendritic cells to live longer, boosting immune response.

To do that, they altered the enzyme so that it targeted a particular domain on the plasma membrane of the cell where signaling occurred, making the action of Akt1 more specific. They then eliminated a small part of the Akt1 molecule that had a negative or inhibitory effect. 'It turned out that the altered molecule was much more potent,' Spencer said. He credited graduate student Dongsu Park with doing much of the work to develop the super form of Akt1.

Using specially designed adenoviruses, he and his colleagues put the modified 'super' Akt1 molec ule into the dendritic cells. 'As predicted, these dendritic cells lived longer and were more potent, both in the laboratory and in mice,' he said. 'It led to the elimination of some very aggressive tumors in the mice.'

In the laboratory, they found that the 'super' Akt1 also has a potent effect on human dendritic cells as well, although it has not been used to treat people yet. He expects that when the enzyme is used in people, the first target will be prostate cancer – a long-standing interest of his laboratory. However, he said, it could be modified to attack other tumors as well.



Source-Eurekalert
MST
'"/>




Related medicine news :

1. Enzyme may be target for obesity drugs
2. Researchers trick Alzheimers Enzyme
3. Enzyme stimulates growth of adult stem cells
4. Enzyme may aid hold back disease
5. Enzyme help destroy cancer cell
6. Enzyme Associated with Memory
7. Enzyme Associated With Memory
8. Brain Enzyme Found To Regulate Weight
9. New Enzyme Identified For Arthritis
10. Enzyme for treatment of arthritis
11. An Enzyme That Turns a One –time Experience into a long-time Memor
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/20/2017)... ... January 20, 2017 , ... ... enhance people’s everyday lives, recently attended the January ECRM Trade Show in Hilton ... is known for its large range of supplements that keep the body functioning ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Mary Magdalene: Grace is Greater than Sin”: ... who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” is the ... an educator interacting with countless women who had little knowledge of the female characters ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Christmas in Suffolk”: ... published author, Sara Seymour, who lives in Lafayette, Indiana where she works in a ... iced coffees and writes. , Published by Christian Faith Publishing, Sara Seymour’s new book ...
(Date:1/19/2017)... (PRWEB) , ... January 20, 2017 , ... Today, the ... to participate in four of CMS’s Alternative Payment Models (APMs) in 2017. Clinicians who ... patients. APMs are an important part of the Administration’s effort to build a ...
(Date:1/19/2017)... , ... January 19, 2017 , ... This month, the ... that the name of their drug rehab center in Delray Beach, Florida has been ... that not only stars such as Philip Seymour Hoffman and Chris Farley are dying ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... YORK , Jan. 19, 2017 This ... the current and future scenario of the global market. ... rising opioid consumption. Severe chronic constipation is a major ... to traditional laxatives. Hence, novel targeted therapy has been ... OIC sufferers, launch of targeted medicines, and growing awareness ...
(Date:1/19/2017)... 19, 2017  Stealth BioTherapeutics Inc. ( Stealth ), ... dysfunction, today announced new additions to its senior leadership ... Medical Officer, and Daniel Geffken as interim ... Jim Carr , Pharm.D. has been promoted to Chief ... to welcome Doug and Daniel to our management team, ...
(Date:1/19/2017)... 2017 According to a study conducted by ... to witness a CAGR of 6.5% during the forecast period 2016-2024. ... continue to be the leading market for cryotherapy globally during the ... Highlights ... ensuring affordable and adequate supply of gas in order to provide ...
Breaking Medicine Technology: